Latest news with #DICOM
NDTV
08-07-2025
- Health
- NDTV
IIT Delhi Launches Online Executive Programme On AI In Healthcare
The Indian Institute of Technology (IIT) Delhi, in partnership with TeamLease Edtech, has announced a new online executive programme focused on the use of Artificial Intelligence (AI) in Healthcare. Aimed at professionals in medicine, technology, and data science, the six-month course is set to begin on November 1, 2025, with applications open until July 31, 2025. This programme is designed to help doctors, engineers, data analysts, and med-tech entrepreneurs learn how AI can be used to improve patient care, public health systems, hospital operations, and diagnostics. Participants do not need prior experience in AI or coding to apply. Classes will be held online on weekends, and the course includes hands-on projects, expert guidance from IIT Delhi faculty, and real-world clinical data. Participants will also work on a capstone project mentored by experts from IIT Delhi and AIIMS. Key Highlights Course Duration: 6 months (November 1, 2025 - May 2, 2026) Mode: Online Fee: Rs 1,20,000 + 18% GST (Payable in two installments) Deadline to Apply: July 31, 2025 Programme Type: eVIDYA Course Modules Include Basics of AI, Machine Learning, and Deep Learning Analysis of Healthcare and Clinical Big Data Predictive Analytics and AI Models AI Automation in Healthcare Public Health & Population Analytics Real-world tools and 10+ case studies Capstone Project & Industry Roundtables Learning Outcomes Learn to apply AI in diagnostics, treatment, and healthcare automation Work with real clinical data like EMRs, imaging, genomics, and IoT sensors Build, evaluate, and deploy AI models using industry standards like FHIR and DICOM Solve real healthcare challenges under expert mentorship Admissions are currently open. For more details and to apply, interested candidates can visit the official IIT Delhi Continuing Education Programme (CEP) portal.
Yahoo
30-05-2025
- Business
- Yahoo
Danaher and AstraZeneca to develop diagnostic tools and tests
Danaher Corporation has announced a collaboration with AstraZeneca for diagnostic tools and tests development and commercialisation, which will aid clinicians in identifying individuals who may benefit from precision medicines. This collaboration will leverage the resources of the newly opened Danaher Centers for Enabling Precision Medicine to streamline the development process. The first product to be developed through this alliance will utilise technologies from Danaher's subsidiary, Leica Biosystems. The initial focus will be on creating computational and digital pathology products, as well as AI-assisted algorithms to improve diagnosis and identify patients likely to respond to targeted therapies. Leica is said to have developed digital pathology solutions and is scaling these technologies for clinical use across its global laboratory network. To expedite this, Leica has committed to the open-access Digital Imaging and Communications in Medicine (DICOM) standard, promoting interoperability and workflow connectivity. AstraZeneca oncology haematology research and development (R&D) executive vice-president Susan Galbraith said: "The transformative potential of next-wave precision medicines such as antibody-drug conjugates will depend on our ability to identify the patients most likely to benefit from them. "Our partnership with Danaher and Leica Biosystems underscores our commitment to pioneering AI-based diagnostics, which can improve patient selection, and our belief that collaboration is a critical accelerant for such progress." Danaher's knowledge in science and technology is pivotal for enabling quick diagnoses and decreasing the time and expenses associated with discovering, developing, and delivering the therapies. In August 2023, Danaher signed an agreement to acquire all outstanding shares of UK-based protein consumables supplier Abcam in a transaction valued at $5.7bn. "Danaher and AstraZeneca to develop diagnostic tools and tests" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at expanding precision medicine. Leveraging DHR's newly launched Centers for Enabling Precision Medicine, the collaboration will focus on creating AI-powered diagnostics to help clinicians better identify which patients are most likely to benefit from targeted therapies, such as next-generation antibody-drug conjugates. A handshake between two men in the lobby of a modern office building, signifying the formation of a Master Limited Partnership. The partnership's first initiative will utilize technologies from Leica Biosystems, a Danaher Corporation (NYSE:DHR) subsidiary renowned for its digital pathology solutions. The initial emphasis will be on digital and computational pathology products and AI-assisted algorithms, aiming to improve diagnostic accuracy and patient selection for precision treatments. Leica Biosystems is also committed to advancing interoperability in clinical workflows through open-access DICOM standards. Danaher Corporation (NYSE:DHR) Executive Vice President Julie Sawyer Montgomery highlighted the goal of increasing access to precision medicines so that no patients are left behind, while AstraZeneca PLC (NASDAQ:AZN)'s Susan Galbraith underscored the critical role of AI-based diagnostics in matching patients with the most effective therapies. Both companies view this collaboration as a significant step toward global digital transformation in pathology and a milestone in delivering personalized healthcare solutions worldwide While we acknowledge the potential of DHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DHR and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
GE HealthCare and FPT Expand Strategic Partnership to Drive AI-Powered Healthcare Innovation
HANOI, Vietnam, April 02, 2025--(BUSINESS WIRE)--Global IT firm FPT and GE HealthCare announced a Strategic Cooperation Agreement, expanding their commercial alliance to advance product strategy and development, and establish an FPT Competency Center in Vietnam. This deepening collaboration reflects a strategic shift from project-based engagement to a long-term alliance aimed at accelerating the adoption of AI-driven solutions, enhancing operational efficiency, and improving patient care. As part of the commercial alliance, FPT will become a channel partner for GE HealthCare, jointly promoting and delivering GE HealthCare's digital solutions in Vietnam and throughout its country network. FPT also plans on collaborating with GE HealthCare's Science & Technology Office and affiliates to co-develop new and further develop GE HealthCare's existing and new digital healthcare products. A key highlight of the partnership is the establishment of an FPT Competency Center in Vietnam. This center will provide dedicated resources to support product strategy, innovation, portfolio planning, development, and customer onboarding. It will also play a critical role in change management, support services and annual maintenance, ensuring seamless integration and operation in GE HealthCare's digital ecosystem. "As a digital transformation enabler, FPT can co-develop cutting-edge healthcare solutions with GE HealthCare. With nearly two decades of experience delivering solutions to healthcare providers, we see immense opportunities to harness AI to transform the industry, enhance efficiency, and drive smarter decision-making. The establishment of the FPT Competency Center will further accelerate the development of AI-powered solutions, supporting GE HealthCare's mission of creating a healthier future for all," said Pham Minh Tuan, FPT Software Chief Executive Officer and Executive Vice President, FPT Corporation. "GE HealthCare is committed to transforming healthcare through digital innovation. Our partnership with FPT allows us to accelerate the adoption of AI-driven solutions that improve hospital operations, enhance patient care, and optimize medical workflows. Together, we are building a smarter, more connected healthcare ecosystem that empowers healthcare providers, improves patient outcomes and increases access to care worldwide," said Mark Stoesz, President, Enterprise Solutions and Partnerships for International Market, GE HealthCare. FPT boasts nearly 20 years of experience in transforming the healthcare industry. The company has been a trusted partner of global leading healthcare providers, facilitating their journey towards operational excellence and enhanced patient care. FPT is among a few technology firms in Southeast Asia to attain crucial certifications aligned with global standards, including HITRUST, HIPAA, ISO 90001, ISO 13485, HL7, and DICOM. About FPT FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. Committed to elevating Vietnam's position on the global tech map and delivering world-class solutions for global enterprises, the Corporation focuses on five strategic areas: Artificial Intelligence, Automotive, Semiconductor, Digital Transformation, and Green Transformation. In 2024, FPT reported a total revenue of USD 2.47 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT's global IT services, please visit About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. View source version on Contacts Media Contact Mai Duong (Ms.)FPT CorporationFPT Software PR Tran Thu Tra (Ms.)Communications LeadGE HealthCare Sign in to access your portfolio
